PDI Overexpression Improves Vascular Contractility in Aged Blood Vessels

Why It Matters

Reversing age‑induced vascular stiffening could mitigate hypertension and related cardiovascular disease, offering a fresh therapeutic avenue.

Key Takeaways

• PDI overexpression restores aged artery contractility.
• Sulfenylation drives actin polymerization for vessel tension.
• Aging reduces sulfenic acid‑mediated contractile signaling.
• Direct PDI‑actin interaction modulates F‑actin assembly.
• Targeting PDI may treat hypertension and arterial stiffness.

Pulse Analysis

Vascular aging is a primary driver of arterial stiffness, hypertension, and atherosclerosis. As smooth muscle cells lose their ability to contract, the mechanical properties of arteries deteriorate, compromising blood flow regulation. Recent research has shifted focus from endothelial dysfunction to the cytoskeletal dynamics of vascular smooth muscle, emphasizing redox‑dependent modifications that govern actin polymerization. Understanding these molecular shifts is essential for clinicians and biotech firms seeking to address the root causes of cardiovascular rigidity.

In a 2025 open‑access study, scientists demonstrated that protein disulfide isomerase (PDI) acts as a redox chaperone that sustains sulfenylation‑driven actin remodeling. Aged mouse arteries exhibited a marked decline in sulfenic‑acid‑linked contractile signaling, resulting in weakened vessel constriction. By genetically overexpressing PDI, researchers restored F‑actin assembly, re‑established contractility, and identified a direct PDI‑actin binding interface modulated by sulfenic acid. These findings illuminate a previously unappreciated link between ER‑resident enzymes and extracellular mechanical performance.

The therapeutic implications are significant. Targeting the PDI‑sulfenylation axis could provide a novel strategy to combat hypertension and age‑related arterial stiffening without relying solely on conventional vasodilators. Future drug development may explore small‑molecule activators of PDI or gene‑therapy approaches to boost its expression in vascular smooth muscle. As the population ages, interventions that restore native contractile mechanisms could reduce cardiovascular morbidity and healthcare costs, positioning PDI as a high‑value target for next‑generation cardiovascular therapeutics.